lung

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced results from an open-label Phase III study of ERBITUX(R)(Cetuximab) plus a taxane and carboplatin in the first-linetreatment for metastatic non-small cell lung cancer (NSCLC). Thestudy did not meet its primary endpoint of progression-freesurvival (PFS) as assessed...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Encouraging Clinical Activity of GSK's Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer

GSK Announces Launch of Largest Ever Phase III Clinical Trial inLung Cancer Treatment PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline today announced final results of a Phase IIproof-of-concept clinical trial of its investigational MAGE-A3Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3positive patients with stage IB or II Non-Small Cell Lung Cancer(NSCLC)...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit ofbioengineering paclitaxel CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced that data published in the 2007Annual Meeting of the American Society of Clinical Oncology (ASCO)abstracts showed reduced medical resource utilization (MRU) andassociated costs with XYOTAX (paclitaxel polyglumex) treatment...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Interim Analysis of Phase 2 Clinical Data Published at the AmericanSociety of Clinical Oncology 43rd Annual Meeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation today released interim findings from its Phase II,multi-center clinical study of Amrubicin, the company'sthird-generation synthetic anthracycline currently in developmentfor the treatment of small cell lung...

Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VIONPHARMACEUTICALS, INC. announced that it presented updated clinicaldata in a poster session at the 43rd Annual Meeting of The AmericanSociety of Clinical Oncology (ASCO) on its lead anticancer agentCloretazine(R) (VNP40101M) as a single agent in a Phase II trial inpatients with relapsed or refractory small cell lung cancer....

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

Company Launches 1,000-Patient Lung Cancer Diversity Study CHICAGO, June 01, 2007 /PRNewswire-FirstCall/ -- Statistics showlung cancer is the leading cause of cancer death inAfrican-Americans, with 21,550 new cases expected to be diagnosedand 16,700 deaths expected this year.(i) Equally devastating, lungcancer is the leading cause of cancer death in Hispanic men and thesecond leading caus...

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Programas Combination Agent with Standard Chemotherapies and Pivotal LungCancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpromising preliminary results from an open-label Phase 2 clinicaltrial of Xcytrin(R) (motexafin gadoliniu...

Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting

-- Data from Picoplatin Phase 1 Colorectal and Prostate CancerTrials To Be Published in 2007 ASCO Proceedings -- SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/-- Poniard Pharmaceuticals, Inc. , a biopharmaceutical companyfocused on oncology, today announced that data from a Phase 2 trialof picoplatin, the Company's lead product candidate, in patientswith small cell lung...

FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer

ROCKVILLE, Md., April 21, 2007-Genentech and FDA notifiedhealthcare professionals of important new safety informationregarding tracheoesophageal (TE) fistula formation in a recentclinical study in patients with limited-stage small cell lungcancer (SCLC). This multicenter, non-randomized, single-arm phaseII clinical trial study combined chemotherapy and radiation plusAvastin. There have b...

New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting

ADDISON, Texas, April 19, 2007 /PRNewswire/ -- New clinicaltrial results for heart transplant patients will be released at theupcoming International Society for Heart and Lung Transplantation(ISHLT) 27th Annual Meeting and Scientific Sessions at the HiltonSan Francisco, April 25-28, 2007. Results show promise for efficacyand safety of immunosuppression therapy and lower incidences ofacut...

Aranesp ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Amgen(NASDAQ: AMGN) today announced the results of the "145 study", arandomized, double-blind, placebo-controlled, multicenter Phase 3study of Aranesp(R) (darbepoetin alfa) in 600 previously untreatedpatients with extensive-stage small-cell lung cancer (SCLC)receiving platinum-containing chemotherapy. The study demonstratedno statistica...

Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - GloucesterPharmaceuticals, Inc., an oncology focused biopharmaceuticalcompany, announced today that encouraging data from a preclinicalstudy examining the combination of romidepsin and erlotinib innon-small cell lung cancer (NSCLC) cell lines derived from humancancer patients were presented at the American Association ofCancer Research Meeti...

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 -AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused onthe discovery and development of novel, targeted cancer medicines,today announced encouraging preclinical data of AV-412, a novel,next generation oral tyrosine kinase inhibitor of EGFR/HER2 usingAVEO's unique EGFR mutant and drug-resistant lung cancer tumormod...

Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ --Telik, Inc. announced the presentation today of results from aPhase 2 clinical trial of the triplet combination of TELCYTA(R)(canfosfamide HCl, TLK286), carboplatin and paclitaxel in thefirst-line treatment of advanced non-small cell lung cancer. Theresults include highly statistically and clinically significantimprovement in bot...

Preclinical Data Show Alfacell's Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells

Poster Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 16, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today announced that in vivo and in vitropreclinical data presented in a poster at the American Associationfor Cancer Research (AACR) Annual Meeting show that ONCONASE(ranpirnase) significantly inhibits tumor growth of non-small celllung cancer (NSCLC) and breast cancer c...

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice

BETHESDA, Md., April 1, 2007--Rapamycin, an FDA-approved drugnormally used to help prevent the body from rejecting organ andbone marrow transplants and also used to coat cardiac stents, washighly effective in preventing the development of tobacco-relatedlung tumors in mice. In a study published in the April 1, 2007issue of Clinical Cancer Research, researchers at the NationalCancer Insti...

Heart Attack Patients Treated With Novel Stem Cell Therapy Experience Significant Improvement in Heart and Lung Function

CHICAGO, March 27, 2007--Heart attack patients who received annew intravenous adult stem cell therapy, Provacel™,experienced a lower number of adverse events, such as cardiacarrhythmias, and had significant improvements in heart, lung andglobal function compared to those who received a placebo, accordingto six-month P...

Curecumin May Be an Effective Treatment for Lung Cancer

MAUI, Hawaii, March 27, 2007 /PRNewswire-FirstCall/ -- BioponicPhytoceuticals, Inc. ("Bioponic" or "the Company") today announcedthat its Curecumin(TM) (a Bioresonant Phytotherapeutic(R) form ofTurmeric containing curcumin in a liquid nasal delivery system) maybe an important treatment for Lung Cancer. In a recent study published in Science Direct, "Induction ofApoptosis in Human L...

In vivo Study Results Demonstrating Potential of Alfacell's Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research

BLOOMFIELD, N.J., March 26, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today announced that in vivo study resultsdemonstrating the potential of ONCONASE (ranpirnase) for thetreatment of non-small cell lung cancer (NSCLC) were recentlypublished in Anticancer Research (2007; 27: 299- 308). Based on the work of Intae Lee, Ph.D., at the University ofPennsylvania, a paper entitl...

Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404

LONDON and FLORENCE, Italy - 8 March 2007 - Cancer drugdeveloper Antisoma plc (LSE: ASM, US OTC: ATSMY) today announcespositive initial findings from its second, confirmatory phase IItrial of AS1404 in non-small cell lung cancer. This 30-patient trial tested an 1800 mg/m2 dose of AS1404 incombination with carboplatin and paclitaxel chemotherapy.Investigators reported a response rat...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conf...